Diabetes Mellitus, Type 2NCT06096311
Improvement of Hyperglycemia/Diabetes in Patients to Improve Safety
An observational study of Diabetes Mellitus, Type 2, run by Northwestern University at 1 site in United States.
Trial summary
The goal of this project is to bring together staff and clinicians from Northwestern University/Northwestern Medical Group/Northwestern Memorial Hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Interviews
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2022to 1 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Provider Group: A clinical multidisciplinary team including inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists. Patient, Caregiver and Layperson Group: The patients who have diabetes/hyperglycemia seen by the Glucose Management Service, the diabetes educator, or the endocrinology service. Caregivers will only be identified by patients if there was a member of their family who helped them with their diabetes management. Laypersons will be identified by research staff as members of the community that can directly advance research and solution development in the field. Stakeholder Group: Any and all stakeholders that are currently involved in the specific care delivery of diabetes.
Who may be able to join
- Provider Group: Multidisciplinary clinical team (including but not limited to inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists)
- Patient, Caregiver and Layperson Group: Patients must have had hyperglycemia or diabetes at Northwestern Memorial Hospital in the last 5 years.
- Stakeholder Group: Involved in the specific care delivery of diabetes
Who cannot join
- Provider Group: None
- Patient, Caregiver, and Layperson Group: Patients will be excluded if they did not have diabetes or had hyperglycemia.
- Stakeholder Group: None
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this project is to bring together staff and clinicians from Northwestern University/Northwestern Medical Group/Northwestern Memorial Hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. There will be 3 different groups for the study: a group of providers [Group 1], a group of patients/caregivers and laypersons [Group 2], and a stakeholder group [Group 3]. Participants will be asked to provide input on potential interventions for a future clinical trial.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Interviews
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewsOther
Interviews
What is being measured
The primary outcome is the main question the study is designed to answer.
Qualitative Results from Interviews
Participants will be asked to provide their thoughts on potential interventions for a future clinical trial.
Measured: Up to one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2023
- Study start1 Apr 2022
- Primary completion7 Aug 2024
- Study completion1 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06096311
- Sponsor's protocol ID
- STU00090319
- Status last verified
- Jun 2026
- First submitted
- 16 Oct 2023
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improvement of Hyperglycemia/Diabetes in Patients to Improve Safety
- ClinicalTrials.gov ID
- NCT06096311
- Acronym / sponsor ID
- STU00090319
- Conditions
- Diabetes Mellitus, Type 2
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Study start
- 1 Apr 2022 (actual)
- Primary completion
- 7 Aug 2024 (actual)
- Study completion
- 1 Dec 2025 (actual)
- First posted
- 23 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this project is to bring together staff and clinicians from Northwestern University/Northwestern Medical Group/Northwestern Memorial Hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. There will be 3 different groups for the study: a group of providers [Group 1], a group of patients/caregivers and laypersons [Group 2], and a stakeholder group [Group 3]. Participants will be asked to provide input on potential interventions for a future clinical trial.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Provider Group: A clinical multidisciplinary team including inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists. Patient, Caregiver and Layperson Group: The patients who have diabetes/hyperglycemia seen by the Glucose Management Service, the diabetes educator, or the endocrinology service. Caregivers will only be identified by patients if there was a member of their family who helped them with their diabetes management. Laypersons will be identified by research staff as members of the community that can directly advance research and solution development in the field. Stakeholder Group: Any and all stakeholders that are currently involved in the specific care delivery of diabetes.
Key inclusion criteria (3 listed)
- Provider Group: Multidisciplinary clinical team (including but not limited to inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists)
- Patient, Caregiver and Layperson Group: Patients must have had hyperglycemia or diabetes at Northwestern Memorial Hospital in the last 5 years.
- Stakeholder Group: Involved in the specific care delivery of diabetes
Key exclusion criteria (3 listed)
- Provider Group: None
- Patient, Caregiver, and Layperson Group: Patients will be excluded if they did not have diabetes or had hyperglycemia.
- Stakeholder Group: None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewsInterviews | Other | – |
Primary outcome
Qualitative Results from Interviews
Time frame: Up to one year
Participants will be asked to provide their thoughts on potential interventions for a future clinical trial.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Northwestern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Qualitative Results from Interviews (time frame: Up to one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026; AzTrials last refreshed its copy on 8 Nov 2026.